Zydus gets zero USFDA observations for Ahmedabad animal health drug manufacturing facility
Ahmedabad: Through a recent BSE filing, Zydus Lifesciences Ltd. has informed that the US Food and Drug Administration (USFDA) has concluded the inspection with nil observations at the group’s animal health drug manufacturing facility at SEZ, Ahmedabad.
The inspection was conducted from 30th May to 2nd June, 2023.
Medical Dialogues team had earlier reported that the USFDA had concluded an inspection with three observations at Zydus Lifesciences's manufacturing facility SEZ-1 located at Pharmez, Ahmedabad.
Read also: USFDA issues 3 observations for Zydus Lifesciences Ahmedabad facility
Zydus Lifesciences Limited, Formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.
Read also: Zydus Lifesciences bags USFDA nod for hypotension injection Ephedrine Sulfate
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.